Use of tiotropium Respimat Soft Mist Inhaler versus HandiHaler and mortality in patients with COPD.

@article{Verhamme2013UseOT,
  title={Use of tiotropium Respimat Soft Mist Inhaler versus HandiHaler and mortality in patients with COPD.},
  author={Katia Verhamme and Ana S M Afonso and Silvana Antonietta Romio and Bruno C. Stricker and Guy Gaston Brusselle and Miriam C. J. M. Sturkenboom},
  journal={The European respiratory journal},
  year={2013},
  volume={42 3},
  pages={606-15}
}
Tiotropium, a long-acting anticholinergic, is delivered via HandiHaler or via Respimat. Randomised controlled trials suggest that use of tiotropium Respimat increases the risk of dying. We compared the risk of mortality between tiotropium Respimat versus HandiHaler. Within the Integrated Primary Care Information database, we defined a source population of patients, aged ≥ 40 years, with ≥ 1 year of follow-up. Based on prescription data, we defined episodes of tiotropium use (Respimat or… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 9 times over the past 90 days. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 30 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 27 references

Long-acting b2-agonists in adult asthma and the pattern of risk of death and severe asthma outcomes: a study using the GPRD

  • F de Vries, E Setakis, B Zhang
  • Eur Respir J
  • 2010

The efficacy of tiotropium administered via Respimat Soft Mist Inhaler or HandiHaler in COPD patients

  • JA van Noord, PJ Cornelissen, JL Aumann
  • Respir Med
  • 2009

Similar Papers

Loading similar papers…